Abstract Number: 1046 • ACR Convergence 2022
Scleroderma Heart Disease
Background/Purpose: Scleroderma heart involvement (SHI) is the 3rd leading cause of death in systemic sclerosis (SSc) [1] following interstitial lung disease (ILD) & pulmonary arterial…Abstract Number: 1048 • ACR Convergence 2022
Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…Abstract Number: 1060 • ACR Convergence 2022
Clinical Characteristics and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data from the International EUSTAR Database
Background/Purpose: This study aimed to characterise the main clinical features of patients with systemic sclerosis (SSc) sine scleroderma (ssSSc) in comparison with the limited cutaneous…Abstract Number: 1059 • ACR Convergence 2022
Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
Background/Purpose: An accurate assessment of nailfold capillaroscopy (NFC) images has great importance in the diagnosis and prognosis of systemic sclerosis (SSc). To overcome some of…Abstract Number: 1053 • ACR Convergence 2022
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Resource Utilization and Gastrointestinal Tract Symptoms in Early Disease
Background/Purpose: Health costs and resource utilization are important in chronic disease management. Systemic sclerosis (SSc) is a multi-organ system disease with outcomes that are often…Abstract Number: 1052 • ACR Convergence 2022
Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey
Background/Purpose: Dedicated data on COVID-19 vaccine-related adverse events (ADEs) in patients with systemic sclerosis (SSc) is limited. Therefore, we aimed to compare all patient-reported ADEs…Abstract Number: 1064 • ACR Convergence 2022
Test-retest Reliability for the Mawdsley Calcinosis Questionnaire for the Measurement of Calcinosis Burden in Patients with Systemic Sclerosis
Background/Purpose: Calcinosis cutis is a debilitating manifestation in systemic sclerosis (SSc) responsible for a high burden of disability and hand dysfunction, contributing as much as…Abstract Number: 1065 • ACR Convergence 2022
Biosamples from VEDOSS Patients Show Pathological Signs of SSc: Opportunity for a Biololgical Diagnosis of Disease
Background/Purpose: The VEDOSS study has recently indicated that more than 50% of patients affected by Raynaud’s phenomenon (RP) and specific SSc anti-nuclear antibodies (ANA) and/or…Abstract Number: 1055 • ACR Convergence 2022
Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe and life-threatening complication of Systemic Sclerosis (SSc). Given the rare nature of SSc, it is challenging to…Abstract Number: 1063 • ACR Convergence 2022
Assessment of Calcinosis in Portuguese Patients with Systemic Sclerosis – a Multicenter Study
Background/Purpose: Calcinosis is a challenging problem among Systemic Sclerosis (SSc) patients with a reported prevalence of 18-49%. We aim to define the prevalence of clinical…Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…Abstract Number: 1070 • ACR Convergence 2022
Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis
Background/Purpose: Assessment of disease burden is crucial in the management of systemic sclerosis (SSc). The patient global assessment (PatGA) is a patient self-reported measure widely…Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…Abstract Number: 1068 • ACR Convergence 2022
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
Background/Purpose: The gastrointestinal tract is commonly affected in systemic sclerosis (SSc). Prior studies have reported an association between higher levels of anti-vinculin antibodies and gastrointestinal…Abstract Number: 1022 • ACR Convergence 2022
Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis
Background/Purpose: Quantification of inflammatory and structural lesions in the sacroiliac joints (SIJ) on MRI scans from patients with axial spondyloarthritis (axSpA) has a growing list…
- « Previous Page
- 1
- …
- 552
- 553
- 554
- 555
- 556
- …
- 2607
- Next Page »
